Journal
JOURNAL OF NEURO-ONCOLOGY
Volume 123, Issue 3, Pages 413-423Publisher
SPRINGER
DOI: 10.1007/s11060-015-1747-8
Keywords
PD-1; CTLA-4; Immune checkpoint; Glioblastoma multiforme
Categories
Funding
- NCI NIH HHS [P30 CA006973] Funding Source: Medline
Ask authors/readers for more resources
Targeted immunotherapy is founded on the principle that augmentation of effector T cell activity in the tumor microenvironment can translate to tumor regression. Targeted checkpoint inhibitors in the form of agonist or antagonist monoclonal antibodies have come to the fore as a promising strategy to activate systemic immunity and enhance T cell activity by blocking negative signals, enhancing positive signals, or altering the cytokine milieu. This review will examine several immune checkpoints and checkpoint modulators that play a role in cancer pathogenesis, with an emphasis on malignant gliomas.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available